Proteasome inhibition as a novel therapeutic target in human cancer

Journal of Clinical Oncology

Volumn 23, Issue 3, 2005, Pages 630-639

  Rajkumar, S Vincent ^a   Richardson, Paul G ^a   Hideshima, Teru ^a   Anderson, Kenneth C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; GROWTH FACTOR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; LACTACYSTIN; MELPHALAN; PACLITAXEL; PROTEASOME; PROTEASOME INHIBITOR; PROTEINASE; STRESS ACTIVATED PROTEIN KINASE; THALIDOMIDE; UBIQUITIN; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN PROTEIN LIGASE; ATP DEPENDENT 26S PROTEASE; BORONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

APOPTOSIS; ARTICLE; BLOATING; CANCER RELAPSE; CELL CYCLE ARREST; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CYTOPENIA; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CANCER; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL; RASH; SOFT TISSUE SARCOMA; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; VOMITING; DISEASE COURSE; DRUG ANTAGONISM; DRUG RESISTANCE; NEOPLASM; PATHOPHYSIOLOGY; REVIEW;

APOPTOSIS; BORONIC ACIDS; CLINICAL TRIALS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; UBIQUITIN;

EID: 14544303662     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.11.030     Document Type: Article

References (93)

1. Adams J: Development of the proteasome inhibitor PS-341. Oncologist 7:9-16, 2002
2. Adams J: Proteasome inhibition in cancer: Development of PS-341. Semin Oncol 28:613-619, 2001
3. Adams J: Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 14:628-634, 2002
4. Ciechanover A: The ubipuitin-proteasome proteolytic pathway. Cell 79:13-21, 1994
5. Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622, 1999
6. Cheson BD: Hematologic malignancies: New developments and future treatments. Semin Oncol 29:33-45, 2002
7. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
8. Anonymous: FDA approves Velcade for multiple myeloma treatment, 2003. http://www.fda.gov/bbs/topics/NEWS/2003/NEW00905.html
9. Adams J, Palombella VJ, Elliott PJ: Proteasome inhibition: A new strategy in cancer treatment. Invest New Drugs 18:109-121, 2000
10. Adams J: Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 6:493-500, 2002
11. Hershko A, Ciechanover A: The ubiquitin system. Annu Rev Biochem 67:425-479, 1998
12. Varshavsky A: The ubiquitin system. Trend Biochem Sci 22:383-387, 1997
13. Palombella VJ, Rando OJ, Goldberg AL, et al: The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78:773-785, 1994
14. Palombella VJ, Conner EM, Fuseler JW, et al: Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A 95:15671-15676, 1998
15. Rock KL, Gramm C, Rothstein L, et al: Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761-771, 1994
16. Spataro V, Norbury C, Harris AL: The ubiquitin-proteasome pathway in cancer. Br J Cancer 77:448-455, 1998
17. Kloetzel PM: Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2:179-187, 2001
18. Almond JB, Cohen GM: The proteasome: A novel target for cancer chemotherapy. Leukemia 16:433-443, 2002
19. Craiu A, Gaczynska M, Akopian T, et al: Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 272:13437-13445, 1997
20. Orlowski M: The multicatalytic proteinase complex, a major extralysosomal proteolytic system. Biochemistry 29:10289-10297, 1990
21. Coux O, Tanaka K, Goldberg AL: Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 65:801-847, 1996
22. Lowe J, Stock D, Jap B, et al: Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 268:533-539, 1995
23. Groll M, Ditzel L, Lowe J, et al: Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386:463-471, 1997
24. Stein RL, Melandri F, Dick L: Kinetic characterization of the chymotryptic activity of the 20S proteasome. Biochemistry 35:3899-3908, 1996
25. Pickart CM, VanDemark AP: Opening doors into the proteasome. Nature Struct Biol 7:999-1001, 2000
26. Seemüller E, Lupas A, Stock D, et al: Proteasome from Thermoplasma acidophilum: A threonine protease. Science 268:579-582, 1995
27. Braun BC, Glickman M, Kraft R, et al: The base of the proteasome regulatory particle exhibits chaperone-like activity. Nature Cell Biol 1:221-226, 1999
28. Groll M, Bajorek M, Kohler A, et al: A gated channel into the proteasome core particle. Nature Struct Biol 7:1062-1067, 2000
29. Orlowski RZ, Eswara JR, Lafond-Walker A, et al: Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58:4342-4348, 1998
30. Drexler HC: Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A 94:855-860, 1997
31. Delic J, Masdehors P, Omura S, et al: The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 77:1103-1107, 1998
32. An B, Goldfarb RH, Siman R, et al: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 5:1062-1075, 1998
33. Traenckner EB, Wilk S, Baeuerle PA: A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 13:5433-5441, 1994
34. Mori S, Tanaka K, Omura S, et al: Degradation process of ligand-stimulated platelet-derived growth factor beta-receptor involves ubiquitin-proteasome proteolytic pathway. J Biol Chem 270:29447-29452, 1995
35. Imajoh-Ohmi S. Kawaguchi T, Sugiyama S, et al: Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 217:1070-1077, 1995
36. Shinohara K, Tomioka M, Nakano H, et al: Apoptosis induction resulting from proteasome inhibition. Biochem J 317:385-388, 1996
37. Tanimoto Y, Onishi Y, Hashimoto S, et al: Peptidyl aldehyde inhibitors of proteasome induce apoptosis rapidly in mouse lymphoma RVC cells. J Biochem 121:542-549, 1997
38. Cusack JC Jr, Liu R, Houston M, et al: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61:3535-3540, 2001
39. Russo SM, Tepper JE, Baldwin AS Jr, et al: Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 50:183-193, 2001
40. Shah SA, Potter MW, McDade TP, et al: 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 82:110-122, 2001
41. Teicher BA, Ara G, Herbst R, et al: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5:2638-2645, 1999
42. Frankel A, Man S, Elliott P, et al: Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 6:3719-3728, 2000
43. Bold RJ, Virudachalam S, McConkey DJ: Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 100:11-17, 2001
44. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427, 2002
45. Aghajanian C, Soignet S, Dizon DS, et al: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505-2511, 2002
46. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076, 2001
47. Mitsiades N, Mitsiades CS, Poulaki V, et al: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 99:14374-14379, 2002
48. Mitsiades N, Mitsiades CS, Richardson PG, et al: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 101:2377-2380, 2003
49. LeBlanc R, Catley LP, Hideshima T, et al: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62:4996-5000, 2002
50. Blade J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998
51. Lee S, Richardson P, Barlogie B, et al: Quality-of-life (QOL) and clinical benefit assessment in patients with relapsed and refractory multiple myeloma (MM) treated with bortezomib. Proc Am Soc Clin Oncol 22:582, 2003 (abstr 2339)
52. Richardson PGG, Barlogie B, Berenson JR, et al: Prognostic factors associated with response in patients with relapsed and refractory multiple myeloma (MM) treated with bortezomib. Proc Am Soc Clin Oncol 22:581, 2003 (abstr 2338)
53. Berenson JR, Jagannath S, Barlogie B, et al: Experience with long-term therapy using the proteasome inhibitor, bortezomib, in advanced multiple myeloma (MM). Proc Am Soc Clin Oncol 22:581, 2003 (abstr 2337)
54. Rajkumar SV, Gertz MA, Kyle RA, et al: Current therapy for multiple myeloma. Mayo Clin Proc 77:813-822, 2002
55. Blade J, Esteve J: Treatment approaches for relapsing and refractory multiple myeloma. Acta Oncol 39:843-847, 2000
56. Rajkumar SV, Fonseca R, Lacy MQ, et al: Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant 23:1267-1272, 1999
57. Jagannath S, Durie BGM, Wolf J, et al: Bortezomib (VELCADE, formerly PS-341) as first-line therapy in patients with multiple myeloma (MM). Blood 102:452a, 2003 (abstr 1650)
58. Goy AH, East K, Mesina O, et al: Report of a phase II study of proteasome inhibitor bortezomib in patients with relapsed or refractory indolent and aggressive B-cell lymphomas. Proc Am Soc Clin Oncol 22:570, 2003 (abstr 2291)
59. O'Connor OA, Wright J, Moskowitz C, et al: Phase II clinical experience with the proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent lymphomas. Proc Am Soc Clin Oncol 22:566, 2003 (abstr 2277)
60. Davis NB, Taber DA, Ansari RH, et al: A phase II trial of PS-341 in patients (pts) with renal cell cancer (RCC). Proc Am Soc Clin Oncol 22: 386, 2003 (abstr 1551)
61. Drucker BJ, Schwartz L, Bacik J, et al: Phase II trial of PS-341 shows response in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 22:386, 2003 (abstr 1550)
62. Maki RG, Kraft A, Demetri GD, et al: A phase II multicenter study of proteasome inhibitor PS-341 (LDP-341, bortezomib) for untreated recurrent or metastatic soft tissue sarcoma (STS); CTEP study 1757. Proc Am Soc Clin Oncol 22:819, 2003 (abstr 3291)
63. Stevenson J, Nho CW, Schick J, et al: Phase II clinical/pharmacodynamic trial of the proteasome inhibitor PS-341 in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 22:202, 2003 (abstr 810)
64. Cheson BD: New drug development in non-Hodgkin lymphomas. Curr Oncol Rep 3:250-259, 2001
65. Hideshima T, Chauhan D, Podar K, et al: Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 28:607-612, 2001
66. Anderson KC: Multiple myeloma: How far have we come? Mayo Clin Proc 78:15-17, 2003
67. Anderson KC: Targeted therapy for multiple myeloma. Semin Hematol 38:286-294, 2001
68. Hideshima T, Chauhan D, Shima Y, et al: Thalidomide and its analogs overcome drug resistance of multiple myeloma cells to conventional therapy. Blood 96:2943-2950, 2000
69. Davies FE, Raje N, Hideshima T, et al: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210-216, 2001
70. Rajkumar SV: Current status of thalidomide in the treatment of cancer. Oncology 15:867-874, 2001
71. Richardson PG, Schlossman RL, Weller E, et al: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063-3067, 2002
72. Hideshima T, Mitsiades C, Akiyama M, et al: Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101:1530-1534, 2003
73. Hideshima T, Chauhan D, Richardson P, et al: NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277:16639-16647, 2002
74. Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: The control of NF-κB activity. Annu Rev Immunol 18:621-663, 2000
75. Gilmore TD, Koedood M, Piffat KA, et al: Rel/NF-kappaB/IkappaB proteins and cancer. Oncogene 13:1367-1378, 1996
76. Karin M: How NF-kappaB is activated: The role of the IkappaB kinase (IKK) complex. Oncogene 18:6867-6874, 1999
77. Mitsiades N, Mitsiades CS, Poulaki V, et al: Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: Therapeutic applications. Blood 99:4079-4086, 2002
78. Karin M, Delhase M: The I kappa B kinase (IKK) and NF-kappa B: Key elements of proinflammatory signalling. Semin Immunol 12:85-98, 2000
79. Gardner RC, Assinder SJ, Christie G, et al: Characterization of peptidyl boronic acid inhibitors of mammalian 20 S and 26 S proteasomes and their inhibition of proteasomes in cultured cells. Biochem J 346:447-454, 2000
80. Hideshima T, Chauhan D, Schlossman R, et al: The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic applications. Oncogene 20:4519-4527, 2001
81. Chauhan D, Uchiyama H, Akbarali Y, et al: Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87:1104-1112, 1996
82. Hazlehurst LA, Damiano JS, Buyuksal I, et al: Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 19:4319-4327, 2000
83. Hazlehurst LA, Dalton WS: Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev 20:43-50, 2001
84. Dalton WS, Bergsagel PL, Kuehl WM, et al: Multiple myeloma, in Schechter GP, Broudy VB, Williams ME (eds): Hematology 2001. Washington, DC, American Society of Hematology, 2001, pp 157-177
85. Sunwoo JB, Chen Z, Dong G, et al: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7:1419-1428, 2001
86. Millennium Pharmaceuticals: VELCADE (bortezomib) for Injection: Prescribing Information. Cambridge, MA, Millennium Pharmaceuticals, Inc, 2003
87. Richardson PG, Briemberg H, Jagannath S, et al: Peripheral neuropathy following bortezomib (VELCADE, formerly PS-341) therapy in patients with advanced multiple myeloma (MM): Characterization and reversibility. Blood 102:149a, 2003 (abstr 512)
88. Jagannath S, Barlogie B, Berenson J, et al: Limited experience from 2 phase 2 trials suggests bortezomib can be given safely in multiple myeloma (MM) patients (pts) with severe renal impairment with comparable responses and toxicities. Blood 102:236a, 2003 (abstr 828)
89. Cusack JC: Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29:21-31, 2003 (suppl 1)
90. Jagannath S, Richardson P, Barlogie B, et al: Phase II trials of bortezomib in combination with dexamethasone in multiple myeloma (MM): Assessment of additional benefits to combination in patients with sub-optimal responses to bortezomib alone. Proc Am Soc Clin Oncol 22:582, 2003 (abstr 2341)
91. Yang HH, Vescio RA, Adams J, et al: A phase I/II study of combination treatment with bortezomib and melphalan (Vc+M) in patients with relapsed or refractory multiple myeloma (MM). Proc Am Soc Clin Oncol 22:582, 2003 (abstr 2340)
92. Orlowski RZ, Voorhees PM, Garcia R, et al: Phase I study of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with refractory hematologic malignancies. Proc Am Soc Clin Oncol 22:200, 2003 (abstr 801)
93. Lenz HJ: Clinical update: Proteasome inhibitors in solid tumors. Cancer Treat Rev 29:41-48, 2003 (suppl 1)